List of publications

@article{monki,

title = {Mpox in people with advanced HIV infection: a global case series},

author = {Oriol Mitjà and Andrea Alemany and Michael Marks and Jezer I. Lezama Mora and Juan Carlos Rodríguez-Aldama and Mayara Secco Torres Silva and Ever Arturo Corral Herrera and Brenda Crabtree-Ramirez and José Luis Blanco and Nicolo Girometti and Valentina Mazzotta and Aniruddha Hazra and Macarena Silva and Juan José Montenegro-Idrogo and Kelly Gebo and Jade Ghosn and María Fernanda Peña Vázquez and Eduardo Matos Prado and Uche Unigwe and Judit Villar-García and Noah Wald-Dickler and Jason Zucker and Roger Paredes and Alexandra Calmy and Laura Waters and Cristina Galvan-Casas and Sharon Walmsley and Chloe M. Orkin and Viviana Leiro and Lucila Marchetta and Patricia Fernandez Pardal and María Inés Figueroa and Pedro Cahn and Katharina Grabmeier-Pfistershammer and Agnes Libois and Laurens Liesenborghs and Beatriz Grinsztejn and Mauro Schechter and Alberto Lemos and Alvaro Furtado Costa and Simone Queiroz Rocha and José Valdez Madruga and Darrell H. S. Tan and Sharmistha Mishra and Shreya Shah and Camila Jorquera and Alberto Castillo and Mauricio Carrión and Nelson Cevallos and Romain Palich and Valerie Pourcher and Emma Rubenstein and Pascal Migaud and Christoph Boesecke and Christian Hoffmann and Konstantinos Protopapas and Silvia Nozza and Anna Maria Cattelan and Cristina Mussini and Antonella Monforte and Raúl Adrian Cruz Flores and Edgar Pérez Barragán and Alma Leticia Rodríguez Guzmán and Dimie Ogoina and Nneka Marian Chika-Igwenyi and Onyeaghala Chizaram and Jenny Valverde López and Angelica García Tello and Maria Ubals and Martí Vall and Adrià Mendoza and Clara Suñer and Bonaventura Clotet and Jordi Bechini and Jose A. Lepe and M. Dolores Navarro-Amuedo and Jose Ignacio Bernadino and Alba Català and Eloy José Tarín Vicente and Borja González Rodríguez and Sergi Rodriguez-Mercader and Francisca Sánchez-Martinez and Esperanza Cañas-Ruano and Laura Parra-Navarro and Finn Filén and Carmen Tallón de Lara and Dominique Braun and Vanja Piezzi and Michael Burkhard and Helen Kovari and Anja Mönch and Jake Dunning and Pedro Simoes and Achyuta Nori and Sarah Keegan and John P. Thornhill and Vanessa Apea and Teymur Noori and Joyce L. Jones and Seth Judson and Elizabeth A. Gilliams and Matthew Hammill and Jeanne Keruly and Andrés F. Henao Martínez and Aung Lin and Jessica So and Kusha Davar and Diana Villareal},

doi = {https://doi.org/10.1016/S0140-6736(23)00273-8},

issn = {0140-6736},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet},

publisher = {Elsevier},

abstract = {BackgroundPeople living with HIV have accounted for 38?50% of those affected in the 2022 multicountry mpox outbreak. Most reported cases were in people who had high CD4 cell counts and similar outcomes to those without HIV. Emerging data suggest worse clinical outcomes and higher mortality in people with more advanced HIV. We describe the clinical characteristics and outcomes of mpox in a cohort of people with HIV and low CD4 cell counts (CD4 <350 cells per mm3).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{sunyer2023,

title = {Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain},

author = {Clara Suñer and Maria Ubals and Eloy José Tarín-Vicente and Adrià Mendoza and Andrea Alemany and Águeda Hernández-Rodríguez and Cristina Casañ and Vicente Descalzo and Dan Ouchi and Aurélien Marc and Àngel Rivero and Pep Coll and Xènia Oller and José Miguel Cabrera and Martí Vall-Mayans and María Dolores Folgueira and María Ángeles Melendez and Manuel Agud-Dios and Elena Gil-Cruz and Alexia Paris de Leon and Aída Ramírez Marinero and Vira Buhiichyk and Cristina Galván-Casas and Roger Paredes and Nuria Prat and Maria-Rosa Sala Farre and Josep Maria Bonet-Simó and Magí Farré and Pablo L. Ortiz-Romero and Bonaventura Clotet and Vicente García-Patos and Jordi Casabona and Jeremie Guedj and Pere-Joan Cardona and Ignacio Blanco and José Ramón Santos and Lucía Bailón and Susana Benet and Jorge Arroyo Andres and Lorena Calderón Lozano and María Carrasco Díaz and Carla Budria Serrano and Enola Crespillo Galán and Ana Isabel Parra Manzano and Pamela Nef Rabadán and Laura Muntané and Cristina Sánchez-Lafuente Doncel and Yesinei Marina Marrero Pueo and Aroa Muñoz Quinto and Marlon Acosta and Patricia Alvarez and Maider Arando and Jorge N. García and Arnau Monforte and Yolanda Maltas Hidalgo and Ramona Hervas Perez and Laura Clotet Romero and Michael Marks and Oriol Mitjà},

doi = {https://doi.org/10.1016/S1473-3099(22)00794-0},

issn = {1473-3099},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet Infectious Diseases},

publisher = {Elsevier},

abstract = {BackgroundMonkeypox DNA has been detected in skin lesions, saliva, oropharynx, urine, semen, and stool of patients infected during the 2022 clade IIb outbreak; however, the viral dynamics within these compartments remain unknown. We aimed to characterise the viral load kinetics over time in various parts of the body.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Tarín-Vicente2022,

title = {Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study},

author = {Eloy José Tarín-Vicente and Andrea Alemany and Manuel Agud-Dios and Maria Ubals and Clara Suñer and Andrés Antón and Maider Arando and Jorge Arroyo-Andrés and Lorena Calderón-Lozano and Cristina Casañ and José Miguel Cabrera and Pep Coll and Vicente Descalzo and María Dolores Folgueira and Jorge N. García-Pérez and Elena Gil-Cruz and Borja González-Rodríguez and Christian Gutiérrez-Collar and Águeda Hernández-Rodríguez and Paula López-Roa and María Ángeles Meléndez and Julia Montero-Menárguez and Irene Muñoz-Gallego and Sara Isabel Palencia-Pérez and Roger Paredes and Alfredo Pérez-Rivilla and María Piñana and Nuria Prat and Aída Ramirez and Ángel Rivero and Carmen Alejandra Rubio-Muñiz and Martí Vall and Kevin Stephen Acosta-Velásquez and An Wang and Cristina Galván-Casas and Michael Marks and Pablo L. Ortiz-Romero and Oriol Mitjà},

doi = {https://doi.org/10.1016/S0140-6736(22)01436-2},

issn = {0140-6736},

year  = {2022},

date = {2022-01-01},

journal = {The Lancet},

volume = {400},

number = {10353},

pages = {661-669},

publisher = {Elsevier},

abstract = {In May, 2022, several European countries reported autochthonous cases of monkeypox, which rapidly spread globally. Early reports suggest atypical presentations. We aimed to investigate clinical and virological characteristics of cases of human monkeypox in Spain.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{ref1,

title = {High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial},

author = {Andrea Alemany and Pere Millat-Martinez and Marc Corbacho-Monné and Pierre Malchair and Dan Ouchi and Anna Ruiz-Comellas and Anna Ramírez-Morros and Joana Rodríguez Codina and Rosa Amado Simon and Sebastian Videla and Gèlia Costes and Mar Capdevila-Jáuregui and Pamela Torrano-Soler and Alba San José and Glòria Bonet Papell and Jordi Puig and Aurema Otero and Jose Carlos Ruibal Suarez and Alvaro Zarauza Pellejero and Ferran Llopis Roca and Orlando Rodriguez Cortez and Vanesa Garcia Garcia and Josep Vidal-Alaball and Anna Millan and Enric Contreras and Joan-Ramon Grifols and Àgueda Ancochea and Ivan Galvan-Femenia and Francini Piccolo Ferreira and Mireia Bonet and Jordi Cantoni and Núria Prat and Jordi Ara and Anna Forcada Arcarons and Magí Farré and Edwards Pradenas and Julià Blanco and Miquel Àngel Rodriguez-Arias and Gema Fernández Rivas and Michael Marks and Quique Bassat and Ignacio Blanco and Bàrbara Baro and Bonaventura Clotet and Oriol Mitjà and Susana Ferrer and Mireia Gallardo and Maria Ubals and Camila González-Beiras and Martí Vall-Mayans and Clara Suñer and Clàudia Laporte-Villar and Aroa Nieto and Xavier Comas-Leon and Zahida Jiménez and Ferran Ramírez-Viaplana and Maria Delgado-Capel and Beatriz Díez Sánchez and Maria Pons Barber and Cristian Gonzalez Ruiz and Laura Navarrete Gonzalez and David González García and Ainhoa Vivero Larraza and Victor Carceles Peiró and Clàudia Roquer López and Neus Robert and Carles Palet and Carlota Gudiol and Pablo Casares Gonzalez and Gemma Arcos Vila and Begoña Flores Aguilera and Graciela Rodríguez-Sevilla and Macarena Dastis Arias and Judit Roca Font and Katherine M. Carrasco Matos and Glòria Saüch Valmaña and Carla Vidal Obradors and Silvia Tarres García and Margarida Curriu Sabatès and Raquel Nieto Rodríguez and Rosa Línio and Míriam Fornos and Natàlia Casamitjana and Eva Alonso and Núria Martínez and Laura Analía Maglio and Laura Comellas Fernandez and Nadia Garcia and Luis Hernández and Maria Isabel González and Anna Bravo and Yolanda García and Silvia Sauleda Oliveras and Tatiana Vertiz and Sergio Benavent and Andrea Sofia Bianco and Joaquim Verdaguer and Ney Nicanor Briones Zambrano and Maria Viozquez Meya and Águeda Hernández and Cristina Casaña Lopez and Antoni E. Bordoy and Victoria González Soler and Montserrat Giménez and Alexa París and Silvia Marfil and Benjamin Trinité and Eulàlia Grau},

doi = {10.1016/S2213-2600(21)00545-2},

issn = {2213-2600},

year  = {2022},

date = {2022-01-01},

journal = {The Lancet Respiratory Medicine},

publisher = {Elsevier},

abstract = {Convalescent plasma has been proposed as an early treatment to interrupt the progression of early COVID-19 to severe disease, but there is little definitive evidence. We aimed to assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{ref1_mitjas,

title = {Monkeypox},

author = {Oriol Mitjà and Dimie Ogoina and Boghuma K. Titanji and Cristina Galvan and Jean-Jacques Muyembe and Michael Marks and Chloe M. Orkin},

doi = {https://doi.org/10.1016/S0140-6736(22)02075-X},

issn = {0140-6736},

year  = {2022},

date = {2022-01-01},

journal = {The Lancet},

publisher = {Elsevier},

abstract = {Monkeypox is a zoonotic illness caused by the monkeypox virus, an Orthopoxvirus in the same genus as the variola, vaccinia, and cowpox viruses. Since the detection of the first human case in the Democratic Republic of the Congo in 1970, the disease has caused sporadic infections and outbreaks, mainly restricted to some countries in west and central Africa. In July, 2022, WHO declared monkeypox a Public Health Emergency of International Concern, on account of the unprecedented global spread of the disease outside previously endemic countries in Africa and the need for global solidarity to address this previously neglected disease. The 2022 outbreak has been primarily associated with close intimate contact (including sexual activity) and most cases have been diagnosed among men who have sex with men, who often present with novel epidemiological and clinical characteristics. In the 2022 outbreak, the incubation period ranges from 7 days to 10 days and most patients present with a systemic illness that includes fever and myalgia and a characteristic rash, with papules that evolve to vesicles, pustules, and crusts in the genital, anal, or oral regions and often involve the mucosa. Complications that require medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of patients and include rectal pain, odynophagia, penile oedema, and skin and anorectal abscesses. Most patients have a self-limited illness; between 1% and 13% require hospital admission (for treatment or isolation), and the case-fatality rate is less than 0·1%. A diagnosis can be made through the presence of Orthopoxvirus DNA in PCRs from lesion swabs or body fluids. Patients with severe manifestations and people at risk of severe disease (eg, immunosuppressed people) could benefit from antiviral treatment (eg, tecovirimat). The current strategy for post-exposure prophylaxis or pre-exposure prophylaxis for people at high risk is vaccination with the non-replicating modified vaccinia Ankara. Antiviral treatment and vaccines are not yet available in endemic countries in Africa.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ayove2014,

title = {Sensitivity and specificity of a rapid point-of-care test for active yaws: a comparative study},

author = {Telek Ayove and Wendy Houniei and Regina Wangnapi and Sibauk V. Bieb and Walter Kazadi and Lisol-Nirau Luke and Clement Manineng and Penias Moses and Raymond Paru and Javan Esfandiari and Pedro L. Alonso and Elisa Lazzari and Quique Bassat and David Mabey and Oriol Mitjà},

doi = {10.1016/S2214-109X(14)70231-1},

issn = {2214-109X},

year  = {2014},

date = {2014-01-01},

journal = {The Lancet Global Health},

volume = {2},

number = {7},

pages = {e415-e421},

publisher = {Elsevier},

abstract = {To eradicate yaws, national control programmes use the Morges strategy (initial mass treatment and biannual resurveys). The resurvey component is designed to actively detect and treat remaining yaws cases and is initiated on the basis of laboratory-supported reactive non-treponemal serology (using the rapid plasma reagin [RPR] test). Unfortunately, the RPR test is available rarely in yaws-endemic areas. We sought to assess a new point-of-care assay?the Dual Path Platform (DPP) syphilis assay, which is based on simultaneous detection of antibodies to treponemal and non-treponemal antigens?for guiding use of antibiotics for yaws eradication. A secondary goal was to ascertain at what timepoint the DPP assay line reverted to negative after treatment.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Ubals2022-tf,

title = {Evaluating the accuracy of self-collected swabs for the diagnoss 

 of monkeypo},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1093/cid/ciad088b,

title = {Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials},

author = {Levine, Adam C and Fukuta, Yuriko and Huaman, Moises A and Ou, Jiangda and Meisenberg, Barry R and Patel, Bela and Paxton, James H and Hanley, Daniel F and Rijnders, Bart J A and Gharbharan, Arvind and Rokx, Casper and Zwaginga, Jaap Jan and Alemany, Andrea and Mitjà, Oriol and Ouchi, Dan and Millat-Martinez, Pere and Durkalski-Mauldin, Valerie and Korley, Frederick K and Dumont, Larry J and Callaway, Clifton W and Libster, Romina and Marc, Gonzalo Perez and Wappner, Diego and Esteban, Ignacio and Polack, Fernando and Sullivan, David J},

doi = {10.1093/cid/ciad088},

issn = {1058-4838},

year  = {2023},

date = {2023-01-01},

urldate = {2023-01-01},

journal = {Clinical Infectious Diseases},

volume = {76},

number = {12},

pages = {2077-2086},

abstract = {Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results.We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022.Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%–6.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%–11.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer.Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1093/cid/ciad088,

title = {Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials},

author = {Adam C Levine and Yuriko Fukuta and Moises A Huaman and Jiangda Ou and Barry R Meisenberg and Bela Patel and James H Paxton and Daniel F Hanley and Bart J A Rijnders and Arvind Gharbharan and Casper Rokx and Jaap Jan Zwaginga and Andrea Alemany and Oriol Mitjà and Dan Ouchi and Pere Millat-Martinez and Valerie Durkalski-Mauldin and Frederick K Korley and Larry J Dumont and Clifton W Callaway and Romina Libster and Gonzalo Perez Marc and Diego Wappner and Ignacio Esteban and Fernando Polack and David J Sullivan},

doi = {10.1093/cid/ciad088},

issn = {1058-4838},

year  = {2023},

date = {2023-01-01},

journal = {Clinical Infectious Diseases},

volume = {76},

number = {12},

pages = {2077-2086},

abstract = {Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results.We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022.Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%–6.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%–11.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer.Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Suñer2022,

title = {Association between two mass-gathering outdoor events and incidence of SARS-CoV-2 infections during the fifth wave of COVID-19 in north-east Spain: A population-based control-matched analysis},

author = {Clara Suñer and Ermengol Coma and Dan Ouchi and Eduardo Hermosilla and Bàrbara Baro and Miquel Àngel Rodríguez-Arias and Jordi Puig and Bonaventura Clotet and Manuel Medina and Oriol Mitjà},

doi = {10.1016/j.lanepe.2022.100337},

issn = {2666-7762},

year  = {2022},

date = {2022-04-01},

journal = {The Lancet Regional Health – Europe},

volume = {15},

publisher = {Elsevier},

abstract = {Many countries have resumed mass-gathering events like music festivals, despite the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreading. In this study, we aimed to assess the effect of two mass-gathering outdoor events, held during a peak of SARS-CoV-2 transmission, on COVID-19 incidence.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{doi:10.1177/00220345221102310b,

title = {Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial},

author = {A. Alemany and D. Perez-Zsolt and D. Raïch-Regué and J. Muñoz-Basagoiti and D. Ouchi and C. Laporte-Villar and B. Baro and N. Henríquez and N. Prat and M. Ochoa Gianinetto and M. Viaplana Gutiérrez and M. Garcia Sánchez-Paniagua and N. Larrosa Henríquez and J. Moreno Vicente and J. Ara and M. A. Rodriguez-Arias and J. Puig and I. Blanco and C. Casañ Lopez and Á. Hernández and A. E. Bordoy and C. Esteban Redondo and V. González Soler and M. Giménez and V. Blanc and R. León and J. Gispert and CPC-COVID GROUP and B. Clotet and N. Izquierdo-Useros and O. Mitjà},

doi = {10.1177/00220345221102310},

year  = {2022},

date = {2022-01-01},

journal = {Journal of Dental Research},

volume = {101},

number = {12},

pages = {1450-1456},

abstract = {The airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via respiratory fluids and droplets suggests that mouthwashes containing substances with virucidal activity can help reduce viral spread. We conducted a multicenter, double-blind, placebo-controlled, randomized trial to assess the virucidal activity of cetylpyridinium chloride (CPC) mouthwashes. Outpatients who tested positive for SARS-CoV-2 infection with or without symptoms were randomized to perform washes and gargles for 1 min with 15 mL of either colored distilled water or 0.07% CPC (Vitis CPC Protect) mouthwash. The study outcomes were the SARS-CoV-2 log10 viral RNA load and the nucleocapsid protein levels, both in saliva at 1 and 3 h after the intervention. In total, 118 patients were enrolled and randomized (mean [SD], age 46 [14] y). Thirteen of 118 participants (11%) did not complete follow-up or had insufficient sample volume for testing and were excluded from the analysis. The assessment of the viral load showed no significant differences between groups at any of the investigated points. However, the levels of SARS-CoV-2 nucleocapsid protein of lysed viruses were significantly higher in the CPC group compared with the control group at 1 h (adjusted difference 269.3 pg/mL; 95% confidence interval [CI], 97.1–441.5) and at 3 h postintervention (561.1 pg/mL; 95% CI, 380.0–742.2). In nonhospitalized patients with asymptomatic or mild symptomatic SARS-CoV-2 infection, a 0.07% CPC mouthwash, compared to placebo, was associated with a significant increase of nucleocapsid protein levels in saliva, indicating enhanced disruption of viral particles.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{ref1c,

title = {High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial},

author = {Andrea Alemany and Pere Millat-Martinez and Marc Corbacho-Monné and Pierre Malchair and Dan Ouchi and Anna Ruiz-Comellas and Anna Ramírez-Morros and Joana Rodríguez Codina and Rosa Amado Simon and Sebastian Videla and Gèlia Costes and Mar Capdevila-Jáuregui and Pamela Torrano-Soler and Alba San José and Glòria Bonet Papell and Jordi Puig and Aurema Otero and Jose Carlos Ruibal Suarez and Alvaro Zarauza Pellejero and Ferran Llopis Roca and Orlando Rodriguez Cortez and Vanesa Garcia Garcia and Josep Vidal-Alaball and Anna Millan and Enric Contreras and Joan-Ramon Grifols and Àgueda Ancochea and Ivan Galvan-Femenia and Francini Piccolo Ferreira and Mireia Bonet and Jordi Cantoni and Núria Prat and Jordi Ara and Anna Forcada Arcarons and Magí Farré and Edwards Pradenas and Julià Blanco and Miquel Àngel Rodriguez-Arias and Gema Fernández Rivas and Michael Marks and Quique Bassat and Ignacio Blanco and Bàrbara Baro and Bonaventura Clotet and Oriol Mitjà and Susana Ferrer and Mireia Gallardo and Maria Ubals and Camila González-Beiras and Martí Vall-Mayans and Clara Suñer and Clàudia Laporte-Villar and Aroa Nieto and Xavier Comas-Leon and Zahida Jiménez and Ferran Ramírez-Viaplana and Maria Delgado-Capel and Beatriz Díez Sánchez and Maria Pons Barber and Cristian Gonzalez Ruiz and Laura Navarrete Gonzalez and David González García and Ainhoa Vivero Larraza and Victor Carceles Peiró and Clàudia Roquer López and Neus Robert and Carles Palet and Carlota Gudiol and Pablo Casares Gonzalez and Gemma Arcos Vila and Begoña Flores Aguilera and Graciela Rodríguez-Sevilla and Macarena Dastis Arias and Judit Roca Font and Katherine M. Carrasco Matos and Glòria Saüch Valmaña and Carla Vidal Obradors and Silvia Tarres García and Margarida Curriu Sabatès and Raquel Nieto Rodríguez and Rosa Línio and Míriam Fornos and Natàlia Casamitjana and Eva Alonso and Núria Martínez and Laura Analía Maglio and Laura Comellas Fernandez and Nadia Garcia and Luis Hernández and Maria Isabel González and Anna Bravo and Yolanda García and Silvia Sauleda Oliveras and Tatiana Vertiz and Sergio Benavent and Andrea Sofia Bianco and Joaquim Verdaguer and Ney Nicanor Briones Zambrano and Maria Viozquez Meya and Águeda Hernández and Cristina Casaña Lopez and Antoni E. Bordoy and Victoria González Soler and Montserrat Giménez and Alexa París and Silvia Marfil and Benjamin Trinité and Eulàlia Grau},

doi = {10.1016/S2213-2600(21)00545-2},

issn = {2213-2600},

year  = {2022},

date = {2022-01-01},

journal = {The Lancet Respiratory Medicine},

publisher = {Elsevier},

abstract = {Convalescent plasma has been proposed as an early treatment to interrupt the progression of early COVID-19 to severe disease, but there is little definitive evidence. We aimed to assess whether early treatment with convalescent plasma reduces the risk of hospitalisation and reduces SARS-CoV-2 viral load among outpatients with COVID-19.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{doi:10.1177/00220345221102310,

title = {Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial},

author = {A. Alemany and D. Perez-Zsolt and D. Raïch-Regué and J. Muñoz-Basagoiti and D. Ouchi and C. Laporte-Villar and B. Baro and N. Henríquez and N. Prat and M. Ochoa Gianinetto and M. Viaplana Gutiérrez and M. Garcia Sánchez-Paniagua and N. Larrosa Henríquez and J. Moreno Vicente and J. Ara and M. A. Rodriguez-Arias and J. Puig and I. Blanco and C. Casañ Lopez and Á. Hernández and A. E. Bordoy and C. Esteban Redondo and V. González Soler and M. Giménez and V. Blanc and R. León and J. Gispert and CPC-COVID GROUP and B. Clotet and N. Izquierdo-Useros and O. Mitjà},

doi = {10.1177/00220345221102310},

year  = {2022},

date = {2022-01-01},

journal = {Journal of Dental Research},

volume = {101},

number = {12},

pages = {1450-1456},

abstract = {The airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via respiratory fluids and droplets suggests that mouthwashes containing substances with virucidal activity can help reduce viral spread. We conducted a multicenter, double-blind, placebo-controlled, randomized trial to assess the virucidal activity of cetylpyridinium chloride (CPC) mouthwashes. Outpatients who tested positive for SARS-CoV-2 infection with or without symptoms were randomized to perform washes and gargles for 1 min with 15 mL of either colored distilled water or 0.07% CPC (Vitis CPC Protect) mouthwash. The study outcomes were the SARS-CoV-2 log10 viral RNA load and the nucleocapsid protein levels, both in saliva at 1 and 3 h after the intervention. In total, 118 patients were enrolled and randomized (mean [SD], age 46 [14] y). Thirteen of 118 participants (11%) did not complete follow-up or had insufficient sample volume for testing and were excluded from the analysis. The assessment of the viral load showed no significant differences between groups at any of the investigated points. However, the levels of SARS-CoV-2 nucleocapsid protein of lysed viruses were significantly higher in the CPC group compared with the control group at 1 h (adjusted difference 269.3 pg/mL; 95% confidence interval [CI], 97.1–441.5) and at 3 h postintervention (561.1 pg/mL; 95% CI, 380.0–742.2). In nonhospitalized patients with asymptomatic or mild symptomatic SARS-CoV-2 infection, a 0.07% CPC mouthwash, compared to placebo, was associated with a significant increase of nucleocapsid protein levels in saliva, indicating enhanced disruption of viral particles.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Alemany2021_self,

title = {Self-collected mid-nasal swabs and saliva specimens, compared with nasopharyngeal swabs, for SARS-CoV-2 detection in mild COVID-19 patients},

author = {Andrea Alemany and Pere Millat-Martinez and Dan Ouchi and Marc Corbacho-Monné and Antoni E. Bordoy and Cristina Esteban and Águeda Hernández and Cristina Casañ and Victoria Gonzalez and Gèlia Costes and Mar Capdevila-Jáuregui and Pamela Torrano-Soler and Alba San José and Jordi Ara and Núria Prat and Bonaventura Clotet and Quique Bassat and Montserrat Gimenez and Ignacio Blanco and Bàrbara Baro and Oriol Mitjà},

doi = {10.1016/j.jinf.2021.09.012},

issn = {0163-4453},

year  = {2021},

date = {2021-12-01},

journal = {Journal of Infection},

volume = {83},

number = {6},

pages = {709-737},

publisher = {Elsevier},

abstract = {Self-collected nasal and saliva samples can be used for SARS-CoV-2 screening.?Self-collected nasal and saliva specimens had a 99% and 90% sensitivity, respectively.?Nasopharyngeal swab viral loads correlate better with nasal than saliva.?Viral load correlations are poorer at day 7, when lower viral loads are observed.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Alemany2021,

title = {Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test},

author = {Andrea Alemany and Bàrbara Baró and Dan Ouchi and Pau Rodó and Maria Ubals and Marc Corbacho-Monné and Júlia Vergara-Alert and Jordi Rodon and Joaquim Segalés and Cristina Esteban and Gema Fernández and Lidia Ruiz and Quique Bassat and Bonaventura Clotet and Jordi Ara and Martí Vall-Mayans and Camila G-Beiras and Ignacio Blanco and Oriol Mitjà},

doi = {10.1016/j.jinf.2020.12.033},

issn = {0163-4453},

year  = {2021},

date = {2021-05-01},

journal = {Journal of Infection},

volume = {82},

number = {5},

pages = {186-230},

publisher = {Elsevier},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marks2021,

title = {Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study},

author = {Michael Marks and Pere Millat-Martinez and Dan Ouchi and Chrissy h. Roberts and Andrea Alemany and Marc Corbacho-Monné and Maria Ubals and Aurelio Tobias and Cristian Tebé and Ester Ballana and Quique Bassat and Bàrbara Baro and Martí Vall-Mayans and Camila G-Beiras and Nuria Prat and Jordi Ara and Bonaventura Clotet and Oriol Mitjà},

doi = {10.1016/S1473-3099(20)30985-3},

issn = {1473-3099},

year  = {2021},

date = {2021-01-01},

journal = {The Lancet Infectious Diseases},

volume = {21},

number = {5},

pages = {629-636},

publisher = {Elsevier},

abstract = {Scarce data are available on what variables affect the risk of transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the development of symptomatic COVID-19, and, particularly, the relationship with viral load. We aimed to analyse data from linked index cases of COVID-19 and their contacts to explore factors associated with transmission of SARS-CoV-2.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{NEJMoa2021801b,

title = {A Cluster-Randomized Trial of Hydroxy-chloro-quine for Prevention of Covid-19},

author = {Oriol Mitjà and Marc Corbacho-Monné and Maria Ubals and Andrea Alemany and Clara Suñer and Cristian Tebé and Aurelio Tobias and Judith Peñafiel and Ester Ballana and Carla A. Pérez and Pol Admella and Núria Riera-Martí and Pep Laporte and Jordi Mitjà and Mireia Clua and Laia Bertran and Maria Sarquella and Sergi Gavilán and Jordi Ara and Josep M. Argimon and Gabriel Cuatrecasas and Paz Cañadas and Aleix Elizalde-Torrent and Robert Fabregat and Magí Farré and Anna Forcada and Gemma Flores-Mateo and Cristina López and Esteve Muntada and Núria Nadal and Silvia Narejos and Aroa Nieto and Nuria Prat and Jordi Puig and Carles Quiñones and Ferran Ramírez-Viaplana and Juliana Reyes-Urueña and Eva Riveira-Muñoz and Lidia Ruiz and Sergi Sanz and Alexis Sentís and Alba Sierra and César Velasco and Rosa M. Vivanco-Hidalgo and Juani Zamora and Jordi Casabona and Martí Vall-Mayans and Camila González-Beiras and Bonaventura Clotet},

doi = {10.1056/NEJMoa2021801},

year  = {2021},

date = {2021-01-01},

journal = {New England Journal of Medicine},

volume = {384},

number = {5},

pages = {417-427},

abstract = {Current strategies for preventing severe acute respiratory syndrome coronavirus 2 

(SARS-CoV-2) infection are limited to nonpharmacologic interventions. Hydroxychloroquine has been proposed as a postexposure therapy to prevent coronavirus 

disease 2019 (Covid-19), but definitive evidence is lacking. (Funded by the crowdfunding campaign YoMeCorono and others; 

BCN-PEP-CoV2 ClinicalTrials.gov number, NCT04304053.)},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Suñer2021,

title = {A retrospective cohort study of risk factors for mortality among nursing homes exposed to COVID-19 in Spain},

author = {Clara Suñer and Dan Ouchi and Miquel Àngel Mas and Rosa Lopez Alarcon and Mireia Massot Mesquida and Núria Prat and Josep Maria Bonet-Simó and Marta Expósito Izquierdo and Irene Garcia Sánchez and Sara Rodoreda Noguerola and Montserrat Teixidó Colet and Joaquim Verdaguer Puigvendrelló and Norma Henríquez and Ramón Miralles and Eugènia Negredo and Marc Noguera-Julian and Michael Marks and Oriol Estrada and Jordi Ara and Oriol Mitjà},

doi = {10.1038/s43587-021-00079-7},

issn = {2662-8465},

year  = {2021},

date = {2021-01-01},

urldate = {2021-01-01},

journal = {Nature Aging},

volume = {1},

number = {7},

pages = {579-584},

abstract = {Long-term care (LTC) facilities have shown remarkably high mortality rates during the coronavirus disease 2019 (COVID-19) outbreak in many countries1, and different risk factors for mortality have been identified in this setting2–5. Using facilities as the unit of analysis, we investigated multiple variables covering facility characteristics and socioeconomic characteristics of the geographic location to identify risk factors for excess mortality from a comprehensive perspective. Furthermore, we used a clustering approach to detect patterns in datasets and generate hypotheses regarding potential relationships between types of nursing homes and mortality trends. Our retrospective analysis included 167 nursing homes providing LTC to 8,716 residents during the COVID-19 outbreak in Catalonia (northeast Spain). According to multiple regression analysis, COVID-19-related and overall mortality at the facility level were significantly associated with a higher percentage of patients with complex diseases, lower scores on pandemic preparedness measures and higher population incidence of COVID-19 in the surrounding population. When grouping nursing homes into eight clusters based on common features, we found higher mortality rates in four clusters, mainly characterized by a higher proportion of residents with complex chronic conditions or advanced diseases, lower scores on pandemic preparedness, being located in rural areas and larger capacity, respectively.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1093/cid/ciaa1009b,

title = {Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial},

author = {Oriol Mitjà and Marc Corbacho-Monné and Maria Ubals and Cristian Tebé and Judith Peñafiel and Aurelio Tobias and Ester Ballana and Andrea Alemany and Núria Riera-Martí and Carla A Pérez and Clara Suñer and Pep Laporte and Pol Admella and Jordi Mitjà and Mireia Clua and Laia Bertran and Maria Sarquella and Sergi Gavilán and Jordi Ara and Josep M Argimon and Jordi Casabona and Gabriel Cuatrecasas and Paz Cañadas and Aleix Elizalde-Torrent and Robert Fabregat and Magí Farré and Anna Forcada and Gemma Flores-Mateo and Esteve Muntada and Núria Nadal and Silvia Narejos and Aroa Nieto and Nuria Prat and Jordi Puig and Carles Quiñones and Juliana Reyes-Ureña and Ferran Ramírez-Viaplana and Lidia Ruiz and Eva Riveira-Muñoz and Alba Sierra and César Velasco and Rosa Maria Vivanco-Hidalgo and Alexis Sentís and Camila G-Beiras and Bonaventura Clotet and Barcelona Post-exposure Prophylaxis for Coronavirus type-2 (BCN PEP-CoV-2) Research Group Martí Vall-Mayans},

doi = {10.1093/cid/ciaa1009},

issn = {1058-4838},

year  = {2020},

date = {2020-01-01},

journal = {Clinical Infectious Diseases},

volume = {73},

number = {11},

pages = {e4073-e4081},

abstract = {No effective treatments for coronavirus disease 2019 (COVID-19) exist. We aimed to determine whether early treatment with hydroxychloroquine (HCQ) would be efficacious for outpatients with COVID-19.Multicenter open-label, randomized, controlled trial conducted in Catalonia, Spain, between 17 March and 26 May 2020. Patients recently diagnosed with <5-day of symptom onset were assigned to receive HCQ (800 mg on day 1 followed by 400 mg once daily for 6 days) or usual care. Outcomes were reduction of viral load in nasopharyngeal swabs up to 7 days after treatment start, disease progression up to 28 days, and time to complete resolution of symptoms. Adverse events were assessed up to 28 days.A total of 293 patients were eligible for intention-to-treat analysis: 157 in the control arm and 136 in the intervention arm. The mean age was 41.6 years (SD, 12.6), mean viral load at baseline was 7.90 log10 copies/mL (SD, 1.82), and median time from symptom onset to randomization was 3 days. No differences were found in the mean reduction of viral load at day 3 (−1.41 vs −1.41 log10 copies/mL in the control and intervention arm, respectively) or at day 7 (−3.37 vs −3.44). Treatment did not reduce risk of hospitalization (7.1% control vs 5.9% intervention) nor shorten the time to complete resolution of symptoms (12 days, control vs 10 days, intervention). No relevant adverse events were reported.In patients with mild COVID-19, no benefit was observed with HCQ beyond the usual care.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitja2023-wfb,

title = {Hydroxychloroquine for treatment of non-hospitalized adults wih 

 COVID-19: A meta-analysis of individual participant data of 

 randomized trial},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{NIETO2023SUBCUT,

title = {Syphilis vaccine: challenges, controversies and opportunities},

author = {Carlos Ávila-Nieto and Núria Pedreño-Lopez and Oriol Mitjà and Bonaventura Clotet and Julà Blanco and Jorge Carrillo},

doi = {https://doi.org/10.3389/fimmu.2023.1126170},

year  = {2023},

date = {2023-01-01},

journal = {Frontiers in Immunology},

volume = {14},

abstract = {Syphilis is a sexually or vertically (mother to fetus) transmitted disease caused by the infection of Treponema pallidum subspecie pallidum (TPA). The incidence of syphilis has increased over the past years despite the fact that this bacterium is an obligate human pathogen, the infection route is well known, and the disease can be successfully treated with penicillin. As complementary measures to preventive campaigns and early treatment of infected individuals, development of a syphilis vaccine may be crucial for controlling disease spread and/or severity, particularly in countries where the effectiveness of the aforementioned measures is limited. In the last century, several vaccine prototypes have been tested in preclinical studies, mainly in rabbits. While none of them provided protection against infection, some prototypes prevented bacteria from disseminating to distal organs, attenuated lesion development, and accelerated their healing. In spite of these promising results, there is still some controversy regarding the identification of vaccine candidates and the characteristics of a syphilis-protective immune response. In this review, we describe what is known about TPA immune response, and the main mechanisms used by this pathogen to evade it. Moreover, we emphasize the importance of integrating this knowledge, in conjunction with the characterization of outer membrane proteins (OMPs), to expedite the development of a syphilis vaccine that can protect against TPA infection.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{MITJA2023100737,

title = {Treatment of bacterial sexually transmitted infections in Europe: gonorrhoea, Mycoplasma genitalium, and syphilis},

author = {Oriol Mitjà and Clara Suñer and Lorenzo Giacani and Martí Vall-Mayans and George-Sorin Tiplica and Jonathan D. C. Ross and Catriona S. Bradshaw},

doi = {https://doi.org/10.1016/j.lanepe.2023.100737},

issn = {2666-7762},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet Regional Health - Europe},

volume = {34},

pages = {100737},

abstract = {This review explores the therapeutic challenges of sexually transmitted infections (STI) in Europe, which include increasing antimicrobial resistance and limited progress in drug discovery. We primarily focus on gonorrhoea, Mycoplasma genitalium, and syphilis infections. For gonorrhoea with escalating resistance rates we explore the possibility of combining ceftriaxone with another antibiotic or using alternative antibiotics to mitigate resistance emergence, and we provide insights on the ongoing evaluation of new antimicrobials, like gepotidacin and zoliflodacin. In the case of M. genitalium, which exhibits high resistance rates to first and second-line treatments, we emphasize the importance of resistance-guided therapy in regions with elevated resistance levels, and highlight the limited alternative options, such as pristinamycin and minocycline. Furthermore, we address the challenges posed by syphilis, where the primary treatment consists of penicillin or doxycycline, with challenges arising in neurosyphilis, allergy, pregnancy, and supply shortages and discuss the ongoing evaluation of alternative antimicrobials (e.g., ceftriaxone, cefixime, linezolid). Our findings identify priority actions and provide concrete solutions for long-term effective management of STIs and antimicrobial resistance mitigation.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{GOKENGIN2023100738,

title = {Prevention strategies for sexually transmitted infections, HIV, and viral hepatitis in Europe},

author = {Deniz Gökengin and Teymur Noori and Andrea Alemany and Carlo Bienkowski and Geoffroy Liegon and Ahmet Çağkan İnkaya and Jorge Carrillo and Georg Stary and Katja Knapp and Oriol Mitja and Jean-Michel Molina},

doi = {https://doi.org/10.1016/j.lanepe.2023.100738},

issn = {2666-7762},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet Regional Health - Europe},

volume = {34},

pages = {100738},

abstract = {The current prevention efforts for STIs, HIV and viral hepatitis in the WHO European Region, especially in the Central and Eastern subregions, are hindered by healthcare disparities, data gaps, and limited resources. In this comprehensive narrative review, we aim to highlight both achievements and persisting challenges while also exploring new developments that could significantly impact the prevention of these infections in the near future. While pre-exposure prophylaxis (PrEP) for HIV has been broadly approved and implemented in 38 out of 53 countries in the region, challenges remain, including cost, limited licensing, and incomplete adherence. We explore innovative approaches like on-demand PrEP, long-acting injectable cabotegravir, and intravaginal rings that have shown promising results, alongside the use of six-monthly lenacapavir, the outcomes of which are pending. Additionally, the potential of doxycycline post-exposure prophylaxis has been discussed, revealing efficacy in reducing chlamydia and syphilis risk, but effectiveness against gonorrhoea being contingent on tetracycline resistance rates, and the need of further data to determine potential resistance development in other bacteria and its impact on the gut microbiome. We examine successful vaccination campaigns against HBV and HPV, the ongoing development of vaccines for chlamydia, syphilis, herpesvirus, and gonorrhoea, and challenges in HIV vaccine research, including lines of research with significant potential like sequential immunization, T-cell responses, and mRNA technology. This review underscores the research endeavors that pave the way for a more resilient and robust approach to combating STIs, HIV, and viral hepatitis in the region.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{MITJA2023100742,

title = {Epidemiology and determinants of reemerging bacterial sexually transmitted infections (STIs) and emerging STIs in Europe},

author = {Oriol Mitjà and Valeska Padovese and Cinta Folch and Isotta Rossoni and Michael Marks and Miquel Angel Rodríguez Arias and Amalio Telenti and Angela Ciuffi and Karel Blondeel and Otilia Mårdh and Jordi Casabona},

doi = {https://doi.org/10.1016/j.lanepe.2023.100742},

issn = {2666-7762},

year  = {2023},

date = {2023-01-01},

journal = {The Lancet Regional Health - Europe},

volume = {34},

pages = {100742},

abstract = {In this scoping review, we offer a comprehensive understanding of the current and recent epidemiology, challenges, and emerging issues related to bacterial sexually transmitted infections (STIs) in the WHO European Region. We endeavour in collating data from both EU/EEA and non- EU/EEA countries, thereby giving a complete picture of the region which highlights the higher notification rates in Northern and Western countries than other regions, likely due to differences in testing, access to testing, and surveillance capacity. We provide an up-to-date review on the current knowledge of determinants and persistent inequities in key populations as well as the use of molecular epidemiology for identifying transmission networks in gonorrhoea and syphilis, and detecting chlamydia mutations that evade molecular diagnosis. Finally, we explore the emerging STIs in the region and the evolving transmission routes of food and waterborne diseases into sexual transmission. Our findings call for harmonized STI surveillance systems, proactive strategies, and policies to address social factors, and staying vigilant for emerging STIs.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Fernandez2021,

title = {Multilocus sequence typing of Treponema pallidum subsp. pallidum in Barcelona},

author = {Candela Fernández-Naval and Maider Arando and Mateu Espasa and Andrés Antón and Miguel Fernández-Huerta and Aroa Silgado and Cristina Pinatar and Francesc Zarzuela and Juan José González-López and Judit Serra-Pladevall and Elena Sulleiro and Tomàs Pumarola and Martí Vall-Mayans and Juliana Esperalba},

doi = {https://doi.org/10.2217/fmb-2021-0037},

year  = {2021},

date = {2021-01-01},

journal = {Future Microbiology},

volume = {16},

number = {13},

pages = {967-976},

abstract = {Aim: To implement the multilocus sequence typing (MLST) methodology in syphilis samples previously characterized by enhanced CDC typing (ECDCT) and macrolide resistance. Materials & methods: MLST was performed on genital ulcer and blood samples by analyzing a region of the tp0136, tp0548 and tp0705 loci using Sanger sequencing. Results: Up to 59/85 (69.4%) of genital ulcer and 4/39 (10.3%) of whole blood samples were fully typed. The most frequent profiles were 1.3.1 (56%) and 1.1.1 (11%). All the 1.3.1 samples typed carried the A2058G mutation, responsible for macrolide resistance. MLST and ECDCT showed similar overall typing yields. Conclusion: Several allelic profiles of T. pallidum subsp. pallidum were identified and classified into two major genetic clades in Barcelona. Our results were similar to that described in Europe.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Haynes2021,

title = {Efficacy of linezolid on textitTreponema pallidum, the syphilis agent: A preclinical study},

author = {Austin M. Haynes and Lorenzo Giacani and Marti Vall Mayans and Maria Ubals and Carles Nieto and Clara Pérez-Mañá and Llorenç Quintó and Emily Romeis and Oriol Mitjà},

doi = {10.1016/j.ebiom.2021.103281},

issn = {2352-3964},

year  = {2021},

date = {2021-01-01},

journal = {EBioMedicine},

volume = {65},

publisher = {Elsevier},

abstract = {Penicillin G, the current standard treatment for syphilis, has important drawbacks, but virtually no preclinical or clinical studies have been performed to identify viable alternatives. We tested, both textitin vitro and textitin vivo, three marketed antibiotics with adequate pharmacological properties to treat syphilis.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Hoyos-Mallecotsextrans-2020-054779,

title = {Drassanes Exprés: a public and confidential testing service for asymptomatic STIs with same-day result notification},

author = {Yannick Hoyos-Mallecot and Jorge Nestor Garcia and Elena Sulleiro and Juliana Esperalba and Paula Salmeron and Francesc Zarzuela and Albert Blanco and Maider Arando and Vicente Descalzo and Luis Lopez and Martí Vall-Mayans and María Jesús Barberá and Judit Serra-Pladevall and Montserrat LLinas and Benito Almirante and Tomas Pumarola and Mateu Espasa},

doi = {10.1136/sextrans-2020-054779},

issn = {1368-4973},

year  = {2021},

date = {2021-01-01},

journal = {Sexually Transmitted Infections},

publisher = {The Medical Society for the Study of Venereal Disease},

abstract = {Background STIs are a major public health concern. Screening programmes for asymptomatic users are key components of STI control. Traditional limitations of screening programmes include low population coverage and delays in treatments, thus reducing the expected impact on STI control. In our centre, the normal time from test to results was 4 days, and 7 days until treatment was established.To reduce time to treatment and to increase population coverage, we developed ‘Drassanes Exprés’, a testing service for asymptomatic STIs. The objectives of this study were to provide a guide for the implementation of a service with these characteristics and to evaluate the results of this intervention.Methods The Drassanes Exprés programme was launched in Spain on 07 November 2016 as a public, confidential and free-of-charge testing service for asymptomatic STIs, with same-day result notification. For this walk-in service, confidentiality was obtained by registering all information into the Laboratory Internal Software instead of the Electronic Patient Records. Samples were processed in a point-of-care laboratory and result notification was provided via mail or short message service.Information about workflow, screening protocols and result interpretation is detailed. Additionally, demographic characteristics, STI prevalence, and time from patients’ sample collection to notification and treatment are analysed.Results Between 07 November 2016 and 07 November 2019, 13 993 users attended the Drassanes Exprés screening programme. Of these, 0.5% were transgender people, 29.3% women, 45.2% men who have sex with men and 25.1% men who have sex with women. The median age was 31 years (range: 26–39 years). Overall, 14.6% of users tested positive for at least one STI. The most prevalent infection was Chlamydia trachomatis (8.3%), followed by Neisseria gonorrhoeae (5.7%), syphilis (1.8%), HIV (0.4%) and hepatitis C virus (0.2%). The median time from test to results was 2.4 hours (range: 2–3.1 hours). Of 2049 users diagnosed with an STI, treatment was achieved in 97.0% of cases; the average time to treatment was 2.0 days.Conclusions Drassanes Exprés is the first public programme for rapid, asymptomatic, STI screening and treatment in Spain. Assessing high-risk practices and providing confidentiality, easy access and rapid results/treatments are key elements in the development of STI screening programmes.Data are available upon reasonable request. All data relevant to the study are included in the article, however more detailed protocols are available upon request.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1371/journal.pntd.0011319b,

title = {Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis},

author = {Abdullah Alshehri and Yashpal S. Chhonker and Veenu Bala and Constant Edi and Catherine M. Bjerum and Benjamin G. Koudou and Lucy N. John and Oriol Mitjà and Michael Marks and Christopher L. King and Daryl J. Murry},

doi = {10.1371/journal.pntd.0011319},

year  = {2023},

date = {2023-01-01},

journal = {PLOS Neglected Tropical Diseases},

volume = {17},

number = {6},

pages = {1-17},

publisher = {Public Library of Science},

abstract = {Background Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals. Methodology / Principal findings In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti–infected (n = 32) and uninfected (n = 24) adults living in Côte d’Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM’s pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/F, 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex. Conclusion/Significance We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF. Trial registration NCT02845713; NCT03664063},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Lucy2022b,

title = {Trial of Three Rounds of Mass Azithromycin Administration for Yaws Eradication},

author = {Lucy N. John and Camila G. Beiras and Wendy Houinei and Monica Medappa and Maria Sabok and Reman Kolmau and Eunice Jonathan and Edward Maika and James K. Wangi and Petra Pospíšilová and David Šmajs and Dan Ouchi and Iván Galván-Femenía and Mathew A. Beale and Lorenzo Giacani and Bonaventura Clotet and Eric Q. Mooring and Michael Marks and Martí Vall-Mayans and Oriol Mitjà},

doi = {https://doi.org/10.1056/NEJMoa2109449},

year  = {2022},

date = {2022-01-01},

journal = {New England Journal of Medicine},

volume = {386},

number = {1},

pages = {47-56},

abstract = {textitTreponema pallidum subspecies textitpertenue causes yaws. Strategies to better control, eliminate, and eradicate yaws are needed. In an open-label, cluster-randomized, community-based trial conducted in a yaws-endemic area of Papua New Guinea, we randomly assigned 38 wards (i.e., clusters) to receive one round of mass administration of azithromycin followed by two rounds of target treatment of active cases (control group) or three rounds of mass administration of azithromycin (experimental group); round 1 was administered at baseline, round 2 at 6 months, and round 3 at 12 months. The coprimary end points were the prevalence of active cases of yaws, confirmed by polymerase-chain-reaction assay, in the entire trial population and the prevalence of latent yaws, confirmed by serologic testing, in a subgroup of asymptomatic children 1 to 15 years of age; prevalences were measured at 18 months, and the between-group differences were calculated.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Lucy2021,

title = {Safety of mass drug coadministration with ivermectin, diethylcarbamazine, albendazole, and azithromycin for the integrated treatment of neglected tropical diseases: a cluster randomized community trial},

author = {Lucy N. John and Camila Gonzalez-Beiras and Marti Vall-Mayans and Reman Kolmau and Wendy Houinei and James Wangi and Michael Marks and Oriol Mitja},

doi = {https://doi.org/10.1016/j.lanwpc.2021.100293},

issn = {2666-6065},

year  = {2021},

date = {2021-01-01},

journal = {The Lancet Regional Health – Western Pacific},

publisher = {Elsevier},

abstract = {Neglected tropical diseases control programmes run separately. For settings with more than one endemic disease, combined mass drug administration (MDA) has potential practical advantages compared with separate programmes but needs confirmation of safety. We assessed the safety of combined MDA for multiple neglected tropical diseases using ivermectin, diethylcarbamazine, albendazole (IDA) and azithromycin (AZI).},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2018,

title = {Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a longitudinal study},

author = {Oriol Mitjà and Charmie Godornes and Wendy Houinei and August Kapa and Raymond Paru and Haina Abel and Camila González-Beiras and Sibauk V. Bieb and James Wangi and Alyssa E. Barry and Sergi Sanz and Quique Bassat and Sheila A. Lukehart},

doi = {10.1016/S0140-6736(18)30204-6},

issn = {0140-6736},

year  = {2018},

date = {2018-01-01},

journal = {The Lancet},

volume = {391},

number = {10130},

pages = {1599-1607},

publisher = {Elsevier},

abstract = {Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marks2018,

title = {Comparative efficacy of low-dose versus standard-dose azithromycin for patients with yaws: a randomised non-inferiority trial in Ghana and Papua New Guinea},

author = {Michael Marks and Oriol Mitjà and Christian Bottomley and Cynthia Kwakye and Wendy Houinei and Mathias Bauri and Paul Adwere and Abdul A. Abdulai and Fredrick Dua and Laud Boateng and James Wangi and Sally-Ann Ohene and Regina Wangnapi and Shirley V. Simpson and Helen Miag and Kennedy K. Addo and Laud A. Basing and Damien Danavall and Kai H. Chi and Allan Pillay and Ronald Ballard and Anthony W. Solomon and Cheng Y. Chen and Sibauk V. Bieb and Yaw Adu-Sarkodie and David C. W. Mabey and Kingsley Asiedu and Wendy Hounei and Sayy-Ann Ohene and Sivuak V. Bieb and David CW Mabey and Nsire Agana and Edwin Ampadu and Kwame Amponsah-Achiano and Asare Bediako and Michael Biredu and Kyei Faried and Ahmed Iddrisu and Nana K. Kotey and George NY Yeboah and Philip El-Duah and Richard Phillips and Fred Binka and Frank Nyonator and Anthony Zunuo and Mercy A. Ackumey and Ivy Amanor and Christian Bnosu and Sieghard Frischmann and Patrick Lammie and Diana Martin and Tun Ye and Eva Christophel and Alexandre Tiendrebeogo and Lasse Vestergard and Quique Bassat and Yazid Abdad and Henson Dima and Bethuel Kotty and Kaiok Mamore and Walerius Manup and Benson Olowau and Enoch O. Agyei and David Agyemang and Ebenezer P. Ako and Prince Antwi and Jane Darko and Ophelia O. Darko and Phylis Darko and Bertha Duodu and Daniel Jabasi and Fuseini L. Karim and Obed K. Koomson and Bernard A. Labri and John Nartey and Randsford Tamatey and Benjamin Yirenkyi and Mercy Arhin and Frank Biney and Juliana O. Danso and Martin A. Dei and Moses Djan and Samuel Sasu and Brefo A. Solomon and Victor Torvinya and Hagar Amankwaah and James Baffoe and Lydia Keteku and Kofi Kondobala and Rita D. Lomotey and Augustina A. Nartey and Paul Oppong and Millicent A. Quainoo and Theophilus Abotsi and Dzighordi Agebshie and Amos Ameamu and Paul Angwaawie and Rose Ayibor and Margaret Mwingmendeli and John Nakodia and Amatus Nambagyira and Dominic Nanga and Nichola Tetteh and Augustine Wanaom},

doi = {10.1016/S2214-109X(18)30023-8},

issn = {2214-109X},

year  = {2018},

date = {2018-01-01},

journal = {The Lancet Global Health},

volume = {6},

number = {4},

pages = {e401-e410},

publisher = {Elsevier},

abstract = {A dose of 30 mg/kg of azithromycin is recommended for treatment of yaws, a disease targeted for global eradication. Treatment with 20 mg/kg of azithromycin is recommended for the elimination of trachoma as a public health problem. In some settings, these diseases are co-endemic. We aimed to determine the efficacy of 20 mg/kg of azithromycin compared with 30 mg/kg azithromycin for the treatment of active and latent yaws.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2017,

title = {Effectiveness of single-dose azithromycin to treat latent yaws: a longitudinal comparative cohort study},

author = {Oriol Mitjà and Camila González-Beiras and Charmie Godornes and Reman Kolmau and Wendy Houinei and Haina Abel and August Kapa and Raymond Paru and Sibauk V. Bieb and James Wangi and Sergi Sanz and Kingsley Asiedu and Sheila A. Lukehart and Quique Bassat},

doi = {10.1016/S2214-109X(17)30388-1},

issn = {2214-109X},

year  = {2017},

date = {2017-01-01},

journal = {The Lancet Global Health},

volume = {5},

number = {12},

pages = {e1268-e1274},

publisher = {Elsevier},

abstract = {Treatment of latent yaws is a crucial component of the WHO yaws eradication strategy to prevent relapse and the resulting transmission to uninfected children. We assessed the effectiveness of single-dose azithromycin to treat patients with latent yaws.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1371/journal.pntd.0004958,

title = {Haemophilus ducreyi DNA is detectable on the skin of asymptomatic children, flies and fomites in villages of Papua New Guinea},

author = {Wendy Houinei and Charmie Godornes and August Kapa and Sascha Knauf and Eric Q. Mooring and Camila González-Beiras and Ronald Watup and Raymond Paru and Paul Advent and Sivauk Bieb and Sergi Sanz and Quique Bassat and Stanley M. Spinola and Sheila A. Lukehart and Oriol Mitjà},

doi = {10.1371/journal.pntd.0004958},

year  = {2017},

date = {2017-01-01},

journal = {PLOS Neglected Tropical Diseases},

volume = {11},

number = {5},

pages = {1-10},

publisher = {Public Library of Science},

abstract = {Author summary Children in rural communities of tropical countries often suffer skin ulcers that are caused by the bacteria Haemophilus ducreyi–causative agent of chancroid- and Treponema pallidum subsp. pertenue -causative agent of yaws-. The currently recommended strategy for yaws eradication is one round of mass drug administration (MDA) with azithromycin. We attempted to find reasons for the limited impact of yaws MDA on the prevalence of H. ducreyi leg ulcers by examining potential sources of infection in healthy carriers, flies, and bed linen. H. ducreyi DNA was found in skin swabs from 20% of asymptomatic children, in 9/10 flies, and 3/6 bed sheets from the houses of children with ulcers. While H. ducreyi DNA has been detected in the genital tract of asymptomatic women without genital ulcers, this is the first report of such detection on the skin of asymptomatic individuals. Importantly, skin cultures obtained from two asymptomatic children yielded viable H. ducreyi, confirming colonization and a potential reservoir of infection. If confirmed to contain viable bacteria, flies and fomites may also contribute to the continued presence of this infection after mass treatment with azithromycin. Our findings provide evidence that persistence of H. ducreyi ulcers after antibiotic MDA is due to the ubiquity of the organism in the environment. Improved hygiene and additional strategies such as repeated rounds of MDA could be able to control such a reservoir.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Gonzalez2016,

title = {Epidemiology of emphHaemophilus ducreyi Infections},

author = {Camila González-Beiras and Michael Marks and Cheng Chen Y. and Sally Roberts and Oriol Mitjà},

doi = {10.3201/eid2201.150425},

year  = {2016},

date = {2016-01-01},

journal = {Emerging Infectious Diseases},

volume = {22},

number = {1},

pages = {1-8},

publisher = {CDC},

abstract = {The global epidemiology of emphHaemophilus ducreyi infections is poorly documented because of difficulties in confirming microbiological diagnoses. We evaluated published data on the proportion of genital and nongenital skin ulcers caused by emphH. ducreyi before and after introduction of syndromic management for genital ulcer disease (GUD). Before 2000, the proportion of GUD caused by emphH. ducreyi ranged from 0.0% to 69.0% (35 studies in 25 countries). After 2000, the proportion ranged from 0.0% to 15.0% (14 studies in 13 countries). In contrast, emphH. ducreyi has been recently identified as a causative agent of skin ulcers in children in the tropical regions; proportions ranged from 9.0% to 60.0% (6 studies in 4 countries). We conclude that, although there has been a sustained reduction in the proportion of GUD caused by emphH. ducreyi, this bacterium is increasingly recognized as a major cause of nongenital cutaneous ulcers.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Oriol2015,

title = {Mass Treatment with Single-Dose Azithromycin for Yaws},

author = {Oriol Mitjà and Wendy Houinei and Penias Moses and August Kapa and Raymond Paru and Russell Hays and Sheila Lukehart and Charmie Godornes and Sibauk Vivaldo Bieb and Tim Grice and Peter Siba and David Mabey and Sergi Sanz and Pedro L. Alonso and Kingsley Asiedu and Quique Bassat},

doi = {10.1056/NEJMoa1408586},

year  = {2015},

date = {2015-01-01},

journal = {New England Journal of Medicine},

volume = {372},

number = {8},

pages = {703-710},

abstract = {Mass treatment with azithromycin is a central component of the new World Health Organization (WHO) strategy to eradicate yaws. Empirical data on the effectiveness of the strategy are required as a prerequisite for worldwide implementation of the plan.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Marks2015,

title = {Challenges and key research questions for yaws eradication},

author = {Michael Marks and Oriol Mitjà and Lasse S. Vestergaard and Allan Pillay and Sascha Knauf and Cheng-Yen Chen and Quique Bassat and Diana L. Martin and David Fegan and Fasihah Taleo and Jacob Kool and Sheila Lukehart and Paul M. Emerson and Anthony W. Solomon and Tun Ye and Ronald C. Ballard and David C. W. Mabey and Kingsley B. Asiedu},

doi = {10.1016/S1473-3099(15)00136-X},

issn = {1473-3099},

year  = {2015},

date = {2015-01-01},

journal = {The Lancet Infectious Diseases},

volume = {15},

number = {10},

pages = {1220-1225},

publisher = {Elsevier},

abstract = {Yaws is endemic in west Africa, southeast Asia, and the Pacific region. To eradicate yaws by 2020, WHO has launched a campaign of mass treatment with azithromycin. Progress has been made towards achievement of this ambitious goal, including the validation of point-of-care and molecular diagnostic tests and piloting of the strategy in several countries, including Ghana, Vanuatu, and Papua New Guinea. Gaps in knowledge need to be addressed to allow refinement of the eradication strategy. Studies exploring determinants of the spatial distribution of yaws are needed to help with the completion of baseline mapping. The finding that emphHaemophilus ducreyi causes lesions similar to yaws is particularly important and further work is needed to assess the effect of azithromycin on these lesions. The integration of diagnostic tests into different stages of the eradication campaign needs investigation. Finally, studies must be done to inform the optimum mass-treatment strategy for sustainable interruption of transmission.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2015,

title = {Global epidemiology of yaws: a systematic review},

author = {Oriol Mitjà and Michael Marks and Diby J. P. Konan and Gilbert Ayelo and Camila Gonzalez-Beiras and Bernard Boua and Wendy Houinei and Yiragnima Kobara and Earnest N. Tabah and Agana Nsiire and Damas Obvala and Fasiah Taleo and Rita Djupuri and Zhang Zaixing and Jürg Utzinger and Lasse S. Vestergaard and Quique Bassat and Kingsley Asiedu},

doi = {10.1016/S2214-109X(15)00011-X},

issn = {2214-109X},

year  = {2015},

date = {2015-01-01},

journal = {The Lancet Global Health},

volume = {3},

number = {6},

pages = {e324-e331},

publisher = {Elsevier},

abstract = {To achieve yaws eradication, the use of the new WHO strategy of initial mass treatment with azithromycin and surveillance twice a year needs to be extended everywhere the disease occurs. However, the geographic scope of the disease is unknown. We aimed to synthesise published and unpublished work to update the reported number of people with yaws at national and subnational levels and to estimate at-risk populations.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2014,

title = {Haemophilus ducreyi as a cause of skin ulcers in children from a yaws-endemic area of Papua New Guinea: a prospective cohort study},

author = {Oriol Mitjà and Sheila A. Lukehart and Gideon Pokowas and Penias Moses and August Kapa and Charmie Godornes and Jennifer Robson and Sarah Cherian and Wendy Houinei and Walter Kazadi and Peter Siba and Elisa Lazzari and Quique Bassat},

doi = {10.1016/S2214-109X(14)70019-1},

issn = {2214-109X},

year  = {2014},

date = {2014-01-01},

urldate = {2014-01-01},

journal = {The Lancet Global Health},

volume = {2},

number = {4},

pages = {e235-e241},

publisher = {Elsevier},

abstract = {Skin infections with ulceration are a major health problem in countries of the south Pacific region. Yaws, caused by Treponema pallidum subspecies pertenue and diagnosed by the presence of skin ulcers and a reactive syphilis serology, is one major cause, but this infection can be confused clinically with ulcers due to other causative agents. We investigated T pallidum pertenue and another bacterium known to cause skin infections in the Pacific islands emphHaemophilus ducreyi as causes of skin ulceration in a yaws-endemic region. Additionally, we identified specific signs and symptoms associated with these causative agents of cutaneous ulcers and compared these findings with laboratory-based diagnoses.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2013,

title = {Yaws},

author = {Oriol Mitjà and Kingsley Asiedu and David Mabey},

doi = {10.1016/S0140-6736(12)62130-8},

issn = {0140-6736},

year  = {2013},

date = {2013-01-01},

journal = {The Lancet},

volume = {381},

number = {9868},

pages = {763-773},

publisher = {Elsevier},

abstract = {Yaws is an infectious disease caused by Treponema pallidum pertenue?a bacterium that closely resembles the causative agent of syphilis?and is spread by skin-to-skin contact in humid tropical regions. Yaws causes disfiguring, and sometimes painful lesions of the skin and bones. As with syphilis, clinical manifestations can be divided into three stages; however, unlike syphilis, mother-to-child transmission does not occur. A major campaign to eradicate yaws in the 1950s and 1960s, by mass treatment of affected communities with longacting, injectable penicillin, reduced the number of cases by 95% worldwide, but yaws has reappeared in recent years in Africa, Asia, and the western Pacific. In 2012, one oral dose of azithromycin was shown to be as effective as intramuscular penicillin in the treatment of the disease, and WHO launched a new initiative to eradicate yaws by 2020.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{Mitjà2012,

title = {Single-dose azithromycin versus benzathine benzylpenicillin for treatment of yaws in children in Papua New Guinea: an open-label, non-inferiority, randomised trial},

author = {Oriol Mitjà and Russell Hays and Anthony Ipai and Moses Penias and Raymond Paru and David Fagaho and Elisa Lazzari and Quique Bassat},

doi = {10.1016/S0140-6736(11)61624-3},

issn = {0140-6736},

year  = {2012},

date = {2012-01-01},

journal = {The Lancet},

volume = {379},

number = {9813},

pages = {342-347},

publisher = {Elsevier},

abstract = {Yaws is an endemic treponematosis and, as such, a neglected tropical disease?is re-emerging in children in rural, tropical areas. Oral azithromycin is effective for syphilis. We assessed the efficacy of azithromycin compared with intramuscular long-acting penicillin to treat patients with yaws.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1093/cid/cix723,

title = {Single-Dose Azithromycin for the Treatment of Haemophilus ducreyi Skin Ulcers in Papua New Guinea},

author = {Camila González-Beiras and August Kapa and Marti Vall-Mayans and Raymond Paru and Sergi Gavilán and Wendy Houinei and Sibauk Bieb and Sergi Sanz and Rosario Martins and Oriol Mitjà},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{10.1093/cid/ciy343,

title = {Multiple Class I and Class II Haemophilus ducreyi Strains Cause Cutaneous Ulcers in Children on an Endemic Island},

author = {Jacob C Grant and Camila González-Beiras and Kristen M Amick and Kate R Fortney and Dharanesh Gangaiah and Tricia L Humphreys and Oriol Mitjà and Ana Abecasis and Stanley M Spinola},

keywords = {},

pubstate = {published},

tppubtype = {article}

}